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Parathyroid hormoneBone biomarkers have been suggested for the risk assessment for osteonecrosis of the jaw, a serious complication
associated with bisphosphonate (BP) use; however, no consensus has been reached. This study investigated the
possible associations between bone biomarkers and the development of bisphosphonates-related osteonecrosis
of the jaw (BRONJ).
This is a case–control study of 37 patients with BRONJ (age, 73.6 ± 11.2 years) who had at least 1 sample avail-
able at diagnosis, out of which, 35 were taking BPs for osteoporosis and 2 patients for bonemetastasis. Age- and
gender-matched 37 patients who had been exposed to BPs for N24 months and had no evidence of BRONJ after
dentoalveolar surgery served as control group. The association between biomarkers (osteocalcin [OC],
deoxypyridinoline [DPD], C-terminal telopeptide of collagen I [CTX], N-terminal telopeptides [NTX], bone-
speciﬁc alkaline phosphatase [BAP], and parathyroid hormone [PTH]) and BRONJ development, the effects of
BP discontinuation on biomarkers, and the performance of biomarkers for risk assessment were investigated.
In our study, the PTH levels were found to be signiﬁcantly higher in BRONJ patients compared to controls
(P b 0.05). But the OC, DPD, CTX, NTX, and BAP levels were not signiﬁcantly different between the 2 groups
(P N 0.05). The CTX level in reference to a 150 pg/mL cutoff was also not signiﬁcant for BRONJ development
(P N 0.05). Among BRONJ patients who discontinued BP, in a linear mixed model, only CTX showed a signiﬁcant
increase over time (β = 0.002, P = 0.007). The cutoff PTH level was N41.52 pg/mL (AUC = 0.719, P = 0.009),
and that of CTX was ≤0.094 ng/mL (AUC = 0.619, P = 0.069).
In conclusion, there is insufﬁcient evidence for the risk prediction for BRONJ of current bone biomarkers; addi-
tional research is necessary.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. Introduction
Since the ﬁrst report of osteonecrosis of the jaw associated with
bisphosphonates administration in 2003, [1] there have been many
efforts to establish the pathophysiologic nature of this disease [2–4].
Although its pathogenesis is still poorly understood, BRONJ
(Bisphosphonate-related osteonecrosis of the jaw) is currently
known to be a disease associated with the oversuppression of bone
remodeling by bisphosphonates (BPs) [2,3,5].
Accordingly, there have been previous attempts to assess the risk for
BRONJ by using bone biomarkers, and Marx et al. [6] have proposed inlofacial Surgery, EwhaWomans
-gu, Seoul 158-710, Republic of
c. Open access under CC BY-NC-SA lictheir uncontrolled retrospective study that serum C-terminal telopeptide
of type I collagen (CTX) is a useful predictor. However, the results of other
clinical studies that used serum markers have been controversial, [7–9]
and no conclusive opinions have been reached about other bone bio-
markers such as N-terminal telopeptide of type I collagen (NTX) and
bone-speciﬁc alkaline phosphatase (BAP) [10–12]. However, such bio-
markers are being used effectively in other ﬁelds, speciﬁcally inmetabolic
and pathologic bone diseases such as osteoporosis and bonemetastasis of
cancer, Paget's disease, and multiple myeloma. These biomarkers are
being used for the prediction of fracture risk, monitoring of BP treatment,
[13] risk determination of skeletal-related events, and determination of
the presence of bone metastases [14]. With the global dependence on
BP use as a nonhormonal treatment of osteoporosis, and the fact that no
biomarkers have been validated for identifying patients at greatest risk
of developing ONJ, there is a pressing need to establish biomarkers for
the risk assessment of BRONJ.
The representative bone biomarkers used widely in the domain of
bone disease include those that reﬂect bone degradation, such as CTX,
NTX, and deoxypyridinoline (DPD), as well as those that reﬂect bone
formation, such as BAP and osteocalcin (OC). These biomarkers areense. 
Table 1
Patients' baseline characteristics.
BRONJ group At risk group
Patients (n) 37 37
Age (year) 73.6 (11.2) 71.3 (10.5)
Gender (n) Male 3 3
Female 34 34
Reason for bisphosphonates
administration (n)
Osteoporosis 35 36
Bone metastasis 2 1
Administration route (n) IV 4 2
PO 33 35
Type of bisphosphonates (n) Alendronate 17 18
Risedronate 6 5
Pamidronate 11 13
Zoledronate 3 1
Comorbidities (n) Chemotherapy 2 1
Steroid use 6 8
Diabetesa 7 6
Obesityb 5 7
Renal failure 1 2
Duration of administration
(months)c, median (range)
73 (21–87) 67 (27–94)
Total dose administered (g) Alendronate 20.51 (4.83) 17.46 (2.49)
Risedronate 11.24 (1.24) 9.48 (4.10)
Pamidronate 10.08 (6.32) 11.28 (2.31)
Zoledronate 0.42 (0.13) 0.33 (0.08)
BRONJ group, patients diagnosed as bisphosphonates related osteonecrosis of jaw; At risk
group, age, gender matched control patients administering BPs over 24 months and no
evidence of ONJ after dentoalveolar surgery.
a Serum fasting glucose ≥ 126 mg/dl or diagnosed as diabetes by medical doctor with
current diabetes medication or insulin injection.
b 25 ≤ BMI (kg/m2).
c Analysis by independent t-test, P N 0.05.
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of bone remodeling activity [15].
We hypothesized that abnormal levels of bone biomarkers OC, DPD,
CTX, NTX, BAP, and PTH represent the severity of bone remodeling over-
suppression, and therefore could be used for the risk assessment of
BRONJ. This case–control study was therefore conducted to investigate
the possible associations of biomarkers in patients with BRONJ.
Patients and methods
Study design
To address the research purpose, we designed and implemented a
case–control study. The BRONJ cases and controls were selected from
patients that visited the Department of Oral and Maxillofacial Surgery
at the Ewha Womans University Medical Center in Seoul, Korea, be-
tween January 2006 and December 2012. The BRONJ group was com-
posed of patients who were under current or previous BP treatment,
and with a BRONJ diagnosis according to the deﬁnition of the
American Society of Bone and Mineral Research task force [16].
Nonhealing sites lasting N8 weeks despite continuous antimicrobial
therapy were reconﬁrmed 8 weeks after the time of ﬁrst discovery
through a repeat examination. Of all BRONJ patients, only those that
had completed a clinical laboratory test at least once at the time of
BRONJ diagnosis were included in this study. The control group
consisted of age- (±2 years) and gender-matched patients (1:1) treat-
ed with BPs for 24 months but with no evidence of osteonecrosis after
dentoalveolar surgery. Patients that had received radiotherapy were
excluded in accordance with the deﬁnitions [17] of the American
Association of Oral and Maxillofacial Surgeons.
Data collection
Patient's personal information and type of BP taken, dose, dosage in-
structions, duration of medication use, and indication were recorded.
Through an examination, the location and size of the exposed necrotic
bone, the presence of infection and pain, and the extension of lesions
were recorded. Possible comorbidities, including patient-related factors
(diabetes, obesity, and renal failure) and iatrogenic factors (steroid use,
chemotherapy), were recorded.
Sampling was performed at the time of BRONJ diagnosis and at each
follow-up visit after a drug holiday. The measured values were recorded
by date, on the basis of the BRONJ diagnosis date. To minimize the effect
of food intake and circadian variation, all samples were taken at 7–8 am
after the nothing by mouth (NPO) state. All samples were moved imme-
diately to the laboratory and kept in a cold refrigerator (−80 °C) until
analysis. The available serum was used to measure the serum levels of
CTX (ECLIA; β-CrossLaps/Serum, Roche Diagnostics, Basel, Switzerland),
OC (ECLIA; Osteocalcin, Roche Diagnostics, Basel, Switzerland), BAP
(EIA; Metra BAP EIA kit, Quidel Corporation, San Diego, USA), PTH (PTH;
Roche Diagnostics, Basel, Switzerland), total calcium (Calcium-HR2,
Wako pure chemical industries, Japan), and albumin (Sekisui ALB, Sekisui
medical co., Japan), and the collected urinewas used tomeasure the urine
levels of DPD (EIA; Metra DPD, Quidel Corporation, San Diego, USA) and
NTX (ELISA; Osteo Mak NTx Urine, Wampole, Princeton, USA). All
urine data were corrected with urinary creatinine. Adjusted total calcium
(mg/dL) was calculated by the formula; total calcium (mg/dL) +
0.8 × [4- albumin (g/dL)]. All participants gavewritten informed consent.
This study and access to patients' records were approved by the institu-
tional review board of the EwhaMedical Center, Seoul, Korea (13-08-01).
Statistical analysis
Initially, the association of the duration of BP exposure to BRONJ de-
velopment and the differences of biomarker values between the 2
groups were assessed using an independent t-test. As recommendedby Marx et al. [6], the association between CTX levels in reference to a
cutoff point of 150 pg/mL and the development of BRONJ was assessed
using a χ2 test. To investigate the trend of biomarker levels with time
after BP discontinuation in BRONJ patients, we used a linear mixed
model (LMM) analysis of repeated measures, with the biomarker levels
as continuous outcome variables. Restricted maximum likelihood esti-
mation and type 3 tests of ﬁxed effects were done. Receiver operating
characteristic (ROC) curve analysis was used to evaluate the overall va-
lidity of the biomarkers. Biomarker performance was evaluated on the
basis of the area under the ROC curve (AUC), as well as according to
the sensitivity and speciﬁcity at the cutoff values at which the sum of
the biomarker sensitivity and speciﬁcity was highest (Youden's J statis-
tic). Also, the sensitivity and speciﬁcity at the commonly used standard
of CTX (150 pg/mL) were recorded. P b 0.05 was considered statistical-
ly signiﬁcant. Statistical analysis was done using PASW statistics 18.
Results
From January 2006 to December 2012, we identiﬁed 61 cases of ONJ.
Of these, 37 patients had at least 1 sample available at the time of BRONJ
diagnosis and were included in the present study (age, 73.6 ±
11.2 years, 3 men and 34 women). Then, 37 age- and gender-matched
patients composed the control group. The patients' baseline characteris-
tics are listed in Table 1. Of the 37 patients in the BRONJ group, 35 were
taking BPs for osteoporosis and 2 patients for bone metastasis. Two
patients had a history of chemotherapy use, 8 patients had been using
steroid, and 6 patients had a diagnosis of diabetes. Themedian duration
of BP exposure was 73 months (range, 21–87 months) for the BRONJ
group and 67 months (range, 27–94 months) for the control group
(P N 0.05).
The differences in biomarker values between the 2 groups are listed
in Table 2. The levels of the bone formation markers serum OC and
serum BAP, and those of the bone degradation markers urine DPD,
urine NTX, and serum CTX were not signiﬁcantly different between
the 2 groups; only levels of serum PTH showed a signiﬁcant difference
(P b 0.05). Regarding the serum total calcium and albumin-adjusted
Fig. 2. Receiver operating characteristic (ROC) curves of serum PTH and CTX for screening
the development of BRONJ. Abbreviations; PTH, parathyroid hormone; CTX, C-terminal
telopeptides of type I collagen; BRONJ, bisphosphonate-related osteonecrosis of jaw;
AUC, area under the ROC curve; SE, standard error; CI, conﬁdence intervals. Circle on
ROC curvemean the cut-off valuewithmaximal value of sumof sensitivity and speciﬁcity.
PTH, AUC (95% CI) = 0.719 (0.556–0.882), P = 0.009, cut-off value: N41.52 pg/ml
(sensitivity = 56.52%, speciﬁcity = 86.67%). CTX, AUC (95% CI) = 0.619 (0.499–0.730),
P = 0.069, cut-off value: ≤0.094 ng/ml (sensitivity = 29.73%, speciﬁcity = 89.19%).
Table 2
Values of biomarkers between two groups.
BRONJ group (I) N Non-BRONJ group (II) N P valuea
sOC (ng/mL) 7.92 (4.43) 35 9.84 (5.69) 36 0.118
uDPD (nM/mMcr)c 6.92 (4.22) 35 7.68 (4.92) 36 0.486
sCTX (ng/mL) 0.177 (0.144) 37 0.229 (0.186) 37 0.187
uNTX (nM/mMCr)c 48.91 (34.46) 35 50.09 (31.88) 37 0.881
sBAP (U/L) 25.39 (9.76) 18 31.91 (15.94) 23 0.115
sPTH (pg/mL) 46.67 (13.24) 23 38.06 (6.60) 15 0.012
sCTX 0.15bb 13 (39.4%) 20 (60.6%) 0.102
sCTX 0.15N 24 (58.5%) 17 (41.5%)
Abbreviations; OC, osteocalcin; DPD, deoxypyridinoline; CTX, C-terminal crosslinked
telopeptide of type I collagen; NTX, N-terminal crosslinked telopeptide of type I
collagen; BAP, bone-speciﬁc alkaline phosphatase; PTH, parathyroid hormone.
a Acquired by independent t-test for OC, DPD, CTX, NTX, BAP, PTH and chi-square test
for CTX 0.15.
b CTX 0.15; The CTX level in reference to a 150 pg/ml cutoff.
c Urine sample of DPD, NTX was corrected with urinary creatinine.
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9.09 ± 0.84, respectively) were signiﬁcantly lower than that of Non-
BRONJ group (n = 24; 9.36 ± 0.51 and 9.50 ± 0.45, respectively)
(P b 0.05). The serum CTX level in reference to a 150 pg/mL cutoff
was also not signiﬁcant for the development of BRONJ (P N 0.05).
When considering the daily trend of biomarker levels (for OC, DPD,
CTX, and NTX) after BP discontinuation in BRONJ patients, the mixed
model analysis with repeated measures revealed no time trends for
OC (estimated regression coefﬁcient [β] = 0.031, 95% CI −0.001 to
0.063, P = 0.057), DPD (β = 0.004, 95% CI −0.028 to 0.020, P =
0.745), and NTX (β = 0.153, 95% CI −0.036 to 0.342, P = 0.110),
with the exception of CTX (β = 0.002, 95% CI 0.000 to 0.003, P =
0.007) (Fig. 1). That is, the CTX levels of BRONJ patients increased by
2 pg/mL per day from the baseline mean of 177 pg/mL after BP
discontinuation.
In the ROC curve analysis for PTH,whichwas a signiﬁcant biomarker,
the AUC was 0.719 (95% CI 0.556–0.882, P = 0.009) (Fig. 2). The cutoff
value with both maximal sensitivity and speciﬁcity was N41.52 pg/mL.
At this cutoff, the sensitivity and speciﬁcity of PTH for the prediction
of BRONJ development was 56.5% and 86.7%, respectively. For CTX, the
AUC was 0.619 (95% CI 0.499–0.730, P = 0.069) and the cutoff value
was ≤0.094 ng/mL (sensitivity, 29.7%; speciﬁcity, 89.2%). When
150 pg/mL was set as the standard, the sensitivity was 54.1% and the
speciﬁcity was 35.1%.Fig. 1. Time trend of C-terminal telopeptide of type I collagen (CTX) from bisphosphonate
discontinuation inBRONJ patients (n = 37). Estimated regression coefﬁcient (β) = 0.002
(0.000–0.003), P = 0.007, acquired by linear mixed model (LMM) analysis of repeated
measures with values of biomarkers. CTX levels of BRONJ patients increased by 2 pg/mL
per day from the baseline mean of 177 pg/mL after BP discontinuation.Discussion
This study was conducted to investigate the possible associations of
the bone biomarkers OC, CTX, NTX, DPD, BAP, and PTH as risk predictors
of BRONJ. Thus, a case–control study involving patientswith a diagnosis
of BRONJ and an age- and gender-matched control group was
conducted. This study was important in that it was an investigation of
controversial bone biomarkers involving a relatively large BRONJ pa-
tient sample size, at a single institution with a single standard for
BRONJ diagnosis criteria and sampling protocols.
BPs are most often used in the nonhormonal treatment of osteopo-
rosis and are also widely used for cancer metastasis and various bone
diseases. Their use has been increasing steadily, and the associated inci-
dence of BRONJ is also increasing [18]. Clinicians have focused on bone
biomarkers as an effective, inexpensive, and widely applicable tool for
predicting and preventing the incidence of this serious complication.
Despite numerous retrospective studies, however, the use of these bio-
markers remains controversial because of the sample size limitations
due to the rare prevalence of BRONJ, as well as problems in study design
in establishing controls andother study criteria (Table 3) [6–12]. Certain
studies [6,7,12] have set the reference ranges of the manufacturer as a
benchmark comparison; however, reference ranges have not yet been
established except in premenopausal women, and even this varied
among studies [19]. Other studies [9,11] used healthy patients or pa-
tients taking BPs as the control group; however, this method is ﬂawed
because the true control group would be patients who have undergone
dentoalveolar surgery without developing BRONJ.
Despite having a carefully matched control group, this study could
not ﬁnd a relation between biomarkers and BRONJ development, with
the exception of PTH. CTX, NTX, andDPD are the representativemarkers
that can quantify the amount of bone absorbed by osteoclastic activity,
and they have received large interest as risk predictors. However, such
collagen degradation markers have a high degree of analytical and bio-
logical variability [20]. More important, even though these markers
quantify the amount of degradation molecules which are produced by
osteoclastic activity at the time of sampling, they do not necessarily re-
ﬂect the overall decrease in bone remodeling activity caused by BPs
[5,12]. Thus, it is likely that thesemarkers will not be highly meaningful
for predicting the degree of dentoalveolar trauma and restorative capac-
ities of bone that shows suppression of osteoclastic activity and subse-
quent abnormal remodeling, the major pharmacologic effect of BPs.
In the present study, the only biomarker that showed a statistical
signiﬁcance for BRONJ development was serum PTH. Ardine et al. [21]
suggested the involvement of hypocalcemia and secondary
Table 3
Previous clinical studies about associations of bone markers to ONJ.
Author, published year Number of ONJ patients Biomarker Results Control
Marx et al. 2007 [6] 30 CTX Sig No controla
Bagan et al. 2008 [9] 15 CTX n.s. Healthy people matched by age, genderbc
Kunchur et al. 2009 [8] 15 CTX n.s. Referred patients for extraction administering BPs
Kwon et al. 2009 [7] 23 CTX Sig No controla
Lazarovici et al. 2010 [10] 18 CTX b 0.15
PTH
BAP
Sig
n.s.
Sig
BPs treated patients who were taken dentoalveolar
surgery
Choi et al. 2012[11] 41 CTX, BAP
ESR, CRP
n.s.
Sig
Postmenopausal women with BPsc
Morris et al. 2012 [12] 56 NTX, BAP n.s. No controla
Abbreviations; ONJ, osteonecrosis of jaw; BPs, bisphosphonates; OC, osteocalcin; CTX, C-terminal crosslinked telopeptide of type I collagen;NTX,N-terminal crosslinked telopeptide of type
I collagen; BAP, bone-speciﬁc alkaline phosphatase; PTH, parathyroid hormone; CTX b 0.15, The CTX level in reference to a 150 pg/ml cutoff.
a Compared with manufacturer's reference ranges.
b Not exposed to bisphosphonates.
c No statement whether dentoalveolar surgery was performed, and subsequent well-healed surgical wound.
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though conﬂicting study results do exist, [10,22] this inspiration may
serve as an important lead for the investigation of the mechanism be-
hind BRONJ, and additional research is needed. Although novel bio-
marker candidates related to bone remodeling such as serum VEGF
[23] and TRACP 5b [5] have been proposed as risk predictors, these
have not yielded continuous research.
Several reports in the dental literature still recommend that the
serum CTX level should be N150 pg/mL before dental surgery
[6,9,10,24]. However, it is not unusual for patients taking BPs to have
serum CTX levels of b150 pg/mL according to the large-scale FLEX
(Fracture Intervention Trial Long-term Extension) [25] and HORIZON
(Health Outcomes and Reduced Incidence with Zoledronic Acid Once
Yearly) [26] studies. Moreover, even among persons with levels of
b150 pg/mL, patients that developed BRONJ are very rare [25,26]. Also
considering that collagen degradation markers are very likely to fall
within wide limits, there is little basis for planning treatment through
biomarker sampling [20].
On the basis of the increases in CTX after discontinuation of BPs, an
adequate drug holiday before dentoalveolar surgery in at-risk patients
taking BPs has been recommended [6,8]. However, this recommenda-
tion is based on the non-evidence-based assumption that biomarkers
such as CTX are adequate BRONJ risk predictors. There ismuch evidence
indicating that osteoclastic activity increases and BMD decreases on BP
discontinuation, but no evidence that this has a direct relation with
BRONJ development [25]. Even considering the molecular action of
BPs that accumulate in the bone tissue, which are not metabolized
and are released from bone very slowly with an estimated terminal
half-life of 1–10 years, there is still not enough evidence to support
drug holidays [13].
Most important, the lack of predictive ability of biomarkers stems
fromwhether they can reﬂect the local site-speciﬁc status of the jaw re-
gion [12]. Despite the limitations in applicability, therewere a few stud-
ies which explored the use of biochemical markers to predict localized
bone involvement such as mono-ostotic Paget's disease [27,28]. In the
same context, whether novel markers such as α-CTX and TRACP 5b
can be used as new candidates for BRONJ risk assessment is yet to be
proven and requires further research.
Our investigation is limited by the small sample size due to the rare
prevalence of BRONJ. Properly designed prospective trials andmulticen-
ter studies with standardized BRONJ diagnostic criteria and sampling
protocols are urgently needed to conﬁrm the available data about the
development of BRONJ and the potential utility of biomarkers. Laborato-
ry tests with these biomarkers as BRONJ risk predictors will also be
more useful when conducted before dentoalveolar surgery, rather
than at the time of BRONJ diagnosis; this timing has been a limitation
of related studies to date.In conclusion, the results of this study indicate that there is insufﬁ-
cient evidence for the use of OC, DPD, CTX, NTX, BAP, and PTH for
BRONJ risk prediction, and that additional research for investigation of
new biomarker for BRONJ is necessary.
Acknowledgments
This study was supported by the Ewha Global Top5 Grant 2013 of
Ewha Womans University, Seoul, Korea. The authors thank Dr. Woo-
Keun Lee (fellow of laboratory medicine, Ewha medical center) for his
dedicated help.
References
[1] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necro-
sis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–7.
[2] Subramanian G, Cohen HV, Quek SY. A model for the pathogenesis of
bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential
role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:
744–53.
[3] Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat
Rev Rheumatol 2012;8:90–6.
[4] Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the
jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67:61–70.
[5] Cremers S, Farooki A. Biochemical markers of bone turnover in osteonecrosis of the
jaw in patients with osteoporosis and advanced cancer involving the bone. Ann N Y
Acad Sci 2011;1218:80–7.
[6] Marx RE, Cillo Jr JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors,
prediction of risk using serum CTX testing, prevention, and treatment. J Oral
Maxillofac Surg 2007;65:2397–410.
[7] Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal
cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related
osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:2644–8.
[8] Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking
telopeptide test in prevention and management of bisphosphonate-associated
osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:1167–73.
[9] Bagan JV, Jimenez Y, Gomez D, Sirera R, Poveda R, Scully C. Collagen telopeptide
(serum CTX) and its relationship with the size and number of lesions in
osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral
Oncol 2008;44:1088–9.
[10] Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic
bone markers for predicting development of osteonecrosis of the jaw in patients re-
ceiving bisphosphonates. J Oral Maxillofac Surg 2010;68:2241–7.
[11] Choi S-Y, An C-H, Kim S-Y, Kwon T-G. Bone turnover and inﬂammatory markers
of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis patients.
J Oral Maxillofac Surg Med Pathol 2013;25:123–8.
[12] Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, et al. Serum
N-telopeptide and bone-speciﬁc alkaline phosphatase levels in patients with
osteonecrosis of the jaw receiving bisphosphonates for bone metastases. J Oral
Maxillofac Surg 2012;70:2768–75.
[13] Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the in-
vestigation and management of postmenopausal osteoporosis. Osteoporos Int
2008;19:1683–704.
[14] Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, et al. Consensus on the utility of
bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol
2011;80:411–32.
205J.-W. Kim et al. / Bone 57 (2013) 201–205[15] Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of
bone turnover for the prediction of fracture risk and monitoring of osteoporosis treat-
ment: a need for international reference standards. Osteoporos Int 2011;22:391–420.
[16] Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the
American Society for Bone andMineral Research. J BoneMiner Res 2007;22:1479–91.
[17] American Association of Oral and Maxillofacial Surgeons position paper on
bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:
369–76.
[18] Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of
osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral
Maxillofac Surg 2010;68:243–53.
[19] Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, et al. Bone
turnovermarkers in themanagement of postmenopausal osteoporosis. Clin Biochem
2009;42:929–42.
[20] Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal os-
teoporosis and its use in predicting risk of osteonecrosis of the jaw. J BoneMiner Res
2009;24:561–74.
[21] Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could
the long-term persistence of low serum calcium levels and high serum parathyroid
hormone levels during bisphosphonate treatment predispose metastatic breast can-
cer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006;17:1336–7.[22] Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al.
Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothe-
sized candidate gene. J Oral Maxillofac Surg 2009;67:159–61.
[23] Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, et al. Serum
VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the
jaw. J Hematol Oncol 2012;5:56.
[24] Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al.
Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:389–91.
[25] Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of con-
tinuing or stopping alendronate after 5 years of treatment: the Fracture Intervention
Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–38.
[26] Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of
osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data
from the health outcomes and reduced incidence with zoledronic acid once yearly
clinical trials program. J Am Dent Assoc 2010;141:1365–70.
[27] Alvarez L, Guañabens N, Peris P, Vidal S, Ros I, Monegal A, et al. Usefulness of bio-
chemical markers of bone turnover in assessing response to the treatment of Paget's
disease. Bone 2001;29:447–52.
[28] Alvarez L, Peris P, Pons F, Guañabens N, Herranz R, Monegal A, et al. Relationship
between biochemical markers of bone turnover and bone scintigraphic indices in
assessment of Paget's disease activity. Arthritis Rheum 1997;40:461–8.
